home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

62 63 Next >

Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗

January 22, 2024

Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.

Via Talk Markets

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades ↗

January 22, 2024

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.

Via Benzinga

2 Smart Growth Stocks to Buy Hand Over Fist in 2024 ↗

January 21, 2024

These businesses are on paths to extremely bright futures.

Via The Motley Fool

EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker ↗

January 18, 2024

The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.

Via Benzinga

Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 ↗

January 18, 2024

On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.

Via Investor's Business Daily

Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) qualifies as a quality stock. ↗

January 12, 2024

This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)

Via Chartmill

Could Regeneron Stock Help You Retire a Millionaire? ↗

January 10, 2024

The blossoming biotech might give more than a nudge to investors in this project.

Via The Motley Fool

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Via InvestorPlace

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

January 16, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

January 09, 2024

Via Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today ↗

January 05, 2024

Via Benzinga

How Is The Market Feeling About Regeneron Pharmaceuticals? ↗

December 27, 2023

Via Benzinga

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish ↗

January 12, 2024

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)

Via Benzinga

Topics Lawsuit

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

3 health care stocks off to strong starts in 2024

January 10, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

Via MarketBeat

Topics Artificial Intelligence

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes ↗

January 08, 2024

Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.

Via Investor's Business Daily

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

January 05, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering ↗

January 05, 2024

Shares soared and then tumbled Friday after the company offered $275 million in public shares.

Via Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

January 04, 2024

Via Benzinga

2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More) ↗

January 04, 2024

These innovative biotechs likely aren't done rewarding their shareholders.

Via The Motley Fool

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Records 52-Week High Wednesday Morning

January 03, 2024

Via Investor Brand Network

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent ↗

December 28, 2023

Wednesday, a court ruling that found Viatris Inc's (NASDAQ:

Via Benzinga

Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High ↗

December 28, 2023

The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for...

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

December 27, 2023

Via Benzinga

Visualized: The Top S&P 500 Stocks Over 20 Years ↗

December 27, 2023

Via Talk Markets

Topics Stocks

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com